What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
J Med Screen
124 - 131.
To model the likely cost utility of the prevalence round of a screening programme for hepatitis C (HCV) in intravenous drug users (IVDUs) in contact with services in the South and West health region of the UK.
|Title:||What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?|
|Keywords:||Comorbidity, Cost-Benefit Analysis, Enzyme-Linked Immunosorbent Assay, Hepacivirus, Hepatitis C, Humans, Interferon-alpha, Mass Screening, Polymerase Chain Reaction, Prevalence, Sensitivity and Specificity, Substance Abuse, Intravenous|
Archive Staff Only